Zeus Capital Dr Gary Waanders talks to DirectorsTalk about the positive headline results from Allergy Therapeutics Plc (LON:AGY). Gary explains how the vaccine is supposed to benefit patients, what the clinical trial was designed to achieve & it’s results and what this means for the remaining development of the birch pollen vaccine. Also discussed is the phase 3 trial length, approval chances, expected sales forecasts and a fair value estimate for the company.
Dr Gary Waanders is an experienced healthcare analyst having worked in the City since early 2001. He joined Zeus in January 2014 and is responsible for research coverage of all our Life Sciences corporate clients which include companies active in biotechnology, specialty pharmaceuticals, medical technology and clinical research services. He has worked on numerous IPOs and M&A mandates in the UK and Europe and has previously worked at Nomura Code Securities and KBC Peel Hunt. Prior to becoming an analyst, he managed an R&D group at a Canadian biotech company and before that he was a post-doctoral fellow at the Ludwig Institute for Cancer Research, Lausanne Branch, Switzerland. His academic training includes an MBA from the University of Durham Business School and a PhD in Immunology from the Faculty of Medicine at Monash University (Australia) where he also obtained a BSc (Hons) in Immunology and Biochemistry.
Allergy Therapeutics Plc is an international specialty pharmaceutical company focussed on the treatment and diagnosis of allergic disorders including immunotherapy vaccines that cure disease. The Company sells proprietary products and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Formed in 1999 out of Smith Kline Beecham, the company is headquartered in Worthing, UK with MHRA-approved manufacturing facilities and employs c.420 employees.
